DE60238255D1 - Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen - Google Patents
Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungenInfo
- Publication number
- DE60238255D1 DE60238255D1 DE60238255T DE60238255T DE60238255D1 DE 60238255 D1 DE60238255 D1 DE 60238255D1 DE 60238255 T DE60238255 T DE 60238255T DE 60238255 T DE60238255 T DE 60238255T DE 60238255 D1 DE60238255 D1 DE 60238255D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- malignes
- azolic
- dyslipidaemia
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29450501P | 2001-05-30 | 2001-05-30 | |
PCT/US2002/016628 WO2002096357A2 (en) | 2001-05-30 | 2002-05-23 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60238255D1 true DE60238255D1 (de) | 2010-12-23 |
Family
ID=23133727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60238255T Expired - Lifetime DE60238255D1 (de) | 2001-05-30 | 2002-05-23 | Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen |
Country Status (9)
Country | Link |
---|---|
US (2) | US7105556B2 (de) |
EP (1) | EP1401433B1 (de) |
JP (1) | JP4365587B2 (de) |
AT (1) | ATE487493T1 (de) |
CA (1) | CA2449006A1 (de) |
DE (1) | DE60238255D1 (de) |
ES (1) | ES2354149T3 (de) |
HU (1) | HUP0600226A3 (de) |
WO (1) | WO2002096357A2 (de) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2248107T3 (es) * | 1999-08-31 | 2006-03-16 | Incyte San Diego Incorporated | Benciliden-tiazolidindionas y analogos y su utilizacion en el tratamiento de la diabetes. |
TW200300681A (en) * | 2001-11-12 | 2003-06-16 | Ono Pharmaceutical Co | Carboxylic acid derivative compound and medicament containing same as active ingredient |
PL374860A1 (en) * | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
JP4887139B2 (ja) * | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
PE20050157A1 (es) * | 2003-05-20 | 2005-05-17 | Novartis Ag | Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar) |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
RU2006107553A (ru) * | 2003-08-13 | 2007-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз |
US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
EP1699777B1 (de) * | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidylpeptidase-hemmer |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
NZ549716A (en) * | 2004-03-15 | 2010-04-30 | Takeda Pharmaceutical | Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors |
ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
WO2005118555A1 (en) * | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
EP1772149A1 (de) * | 2004-07-27 | 2007-04-11 | Kowa Company. Ltd. | Wirkstoff zur prävention oder behandlung von diabetes |
TW200637553A (en) * | 2004-12-14 | 2006-11-01 | Shionogi & Co | Indlomorphinane derivatives having a carboxy group at 6' position |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
WO2007011524A1 (en) * | 2005-07-14 | 2007-01-25 | Franco Folli | Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome |
WO2007014023A1 (en) * | 2005-07-21 | 2007-02-01 | Valeant Research & Development | Thiazolidinones, oxazolidinones, and pyrrolidinones for hbv |
NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
PE20070458A1 (es) * | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1999108A1 (de) * | 2006-03-28 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Herstellung von (r)-3-aminopiperidin-dihydrochlorid |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
KR20090088854A (ko) * | 2006-09-13 | 2009-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
DK2180787T3 (da) | 2007-08-01 | 2014-02-03 | Univ Pittsburgh | Nitrooliesyremodulering af type ii-diabetes |
DK2200606T3 (en) | 2007-09-10 | 2017-12-04 | Janssen Pharmaceutica Nv | PROCEDURE FOR THE PREPARATION OF RELATIONSHIP USED AS INHIBITORS OF SGLT |
DK2280928T3 (en) | 2008-05-01 | 2018-11-05 | Complexa Inc | Vinyl-substituted fatty acids |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
WO2009155439A2 (en) | 2008-06-19 | 2009-12-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
CA2769624C (en) | 2009-07-31 | 2018-09-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Electrophilic fatty acid derivatives as anti-inflammatory agents |
EP2483233A4 (de) | 2009-10-02 | 2013-08-14 | Complexa Inc | Heteroatom mit substituierten fettsäuren |
EP2488515B1 (de) | 2009-10-14 | 2017-01-04 | Janssen Pharmaceutica NV | Verfahren zur herstellung von verbindungen die als sglt2 inhibitoren verwendbar sind |
WO2011073376A1 (en) * | 2009-12-18 | 2011-06-23 | Euroscreen S.A. | Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43) |
US20120115799A1 (en) | 2010-05-11 | 2012-05-10 | Wenhua Wang | Pharmaceutical formulations |
CA2804144A1 (en) * | 2010-06-28 | 2012-01-12 | Complexa, Inc. | Multi-component pharmaceuticals for treating diabetes |
EA028946B1 (ru) | 2011-04-13 | 2018-01-31 | Янссен Фармацевтика Нв | Способ получения соединений для применения в качестве ингибиторов sglt2 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
WO2013028501A1 (en) | 2011-08-19 | 2013-02-28 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
TN2017000507A1 (en) | 2015-07-07 | 2019-04-12 | H Lundbeck As | Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
CA3000842A1 (en) | 2015-10-02 | 2017-04-06 | Complexa, Inc. | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS584711B2 (ja) | 1978-08-02 | 1983-01-27 | 参天製薬株式会社 | ピロリジン誘導体 |
FR2678938B1 (fr) | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
TWI260321B (en) | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
PT1228067E (pt) | 1999-11-10 | 2004-11-30 | Takeda Chemical Industries Ltd | Compostos heterociclicos de cinco membros com actividade hipoglicemica e hipolipidemica |
-
2002
- 2002-05-22 US US10/153,342 patent/US7105556B2/en not_active Expired - Lifetime
- 2002-05-23 DE DE60238255T patent/DE60238255D1/de not_active Expired - Lifetime
- 2002-05-23 EP EP02737192A patent/EP1401433B1/de not_active Expired - Lifetime
- 2002-05-23 WO PCT/US2002/016628 patent/WO2002096357A2/en active IP Right Grant
- 2002-05-23 CA CA002449006A patent/CA2449006A1/en not_active Abandoned
- 2002-05-23 AT AT02737192T patent/ATE487493T1/de not_active IP Right Cessation
- 2002-05-23 JP JP2002592870A patent/JP4365587B2/ja not_active Expired - Fee Related
- 2002-05-23 HU HU0600226A patent/HUP0600226A3/hu not_active Application Discontinuation
- 2002-05-23 ES ES02737192T patent/ES2354149T3/es not_active Expired - Lifetime
-
2006
- 2006-04-19 US US11/406,799 patent/US7452907B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2002096357A2 (en) | 2002-12-05 |
JP2005506954A (ja) | 2005-03-10 |
HUP0600226A2 (en) | 2006-11-28 |
WO2002096357A3 (en) | 2003-09-25 |
JP4365587B2 (ja) | 2009-11-18 |
ATE487493T1 (de) | 2010-11-15 |
US20030092697A1 (en) | 2003-05-15 |
ES2354149T3 (es) | 2011-03-10 |
US20060189598A1 (en) | 2006-08-24 |
CA2449006A1 (en) | 2002-12-05 |
EP1401433B1 (de) | 2010-11-10 |
US7452907B2 (en) | 2008-11-18 |
EP1401433A4 (de) | 2005-10-12 |
HUP0600226A3 (en) | 2012-09-28 |
US7105556B2 (en) | 2006-09-12 |
EP1401433A2 (de) | 2004-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60238255D1 (de) | Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen | |
DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
NO20024005D0 (no) | Pteridinforbindelser for behandling av psoriasis | |
ATE355293T1 (de) | Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten | |
NO20035327D0 (no) | Biologisk aktive metylen-blått derivater | |
DE60219292D1 (de) | Pyrazolderivate zur behandlung von hiv | |
DE60037892D1 (de) | Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis | |
SE0102439D0 (sv) | New compounds | |
ATE242213T1 (de) | Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz | |
DE60219793D1 (de) | Methode zur behandlung von zytokinvermittelten erkrankungen | |
BR0211473A (pt) | Novos compostos | |
ATE417836T1 (de) | Verfahren und intermediate zur herstellung von retroviralen proteasehemmern | |
ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
DE60100625D1 (de) | Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina | |
DE60318839D1 (de) | 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten | |
ATE316962T1 (de) | Pyrimidin-derivate als selective inhibitoren von cox-2 | |
ATE346614T1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
SE9804212D0 (sv) | Compounds | |
ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
IT1318667B1 (it) | Medicamento antinfiammatorio. | |
DE60231969D1 (de) | sPLA2-INHIBITOREN ZUR BEHANDLUNG VON ARTERIOSKLEROSE | |
TR200302288T2 (tr) | Terapi için yeni bileşikler ve metotlar. |